Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102

Basit Öğe Kaydı
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridGökyer, Ali/0000-0002-1653-6155
dc.authoridHacioglu, Bekir/0000-0001-8490-3239;
dc.authorwosidBilici, Ahmet/E-2062-2018
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidGökyer, Ali/AAQ-5700-2020
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidKurt, Nazmi/JFA-8132-2023
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorKostek, Osman
dc.contributor.authorKurt, Nazmi
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorGokyer, Ali
dc.contributor.authorUstabasioglu, Fethi Emre
dc.contributor.authorKaratas, Fatih
dc.date.accessioned2024-06-12T11:08:25Z
dc.date.available2024-06-12T11:08:25Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC). Methods: A total of 36 mCRC patients, who received regorafenib or TAS-102 in the third-line and subsequent settings were assessed in the analysis. SMM changes were assessed with CT scans findings, and they were categorized into two groups as SMM-loss (SMM decrease >= 2%) and SMM-stable (SMM change <2%). Results: The SMM change after regorafenib therapy was significantly worse compared with TAS-102 therapy (p=0.001). The median overall survival (OS) was longer in SMM-stable group than in SMM-loss group (12.8 months; 95%CI:9.8-15.7) vs. 6.4 months; 95%CI:5.2-7.7, respectively;p=0.04). Cox regression analysis showed that SMM loss was independent prognostic indicator for OS (HR, 2.87; 95%CI: 1.07-7.42, p=0.03). Conclusion: Although patients who received regorafenib had more SMM loss than those who received TAS-102, there was no difference in OS between drugs.en_US
dc.identifier.endpage2204en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue5en_US
dc.identifier.pmid31786894en_US
dc.identifier.scopus2-s2.0-85075000516en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2198en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22424
dc.identifier.volume24en_US
dc.identifier.wosWOS:000501762000062en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectRegorafeniben_US
dc.subjectTAS-102en_US
dc.subjectSarcopeniaen_US
dc.subjectSkeletal Muscle Massen_US
dc.subjectComputed-Tomographyen_US
dc.subjectTreatment Outcomesen_US
dc.subjectSarcopeniaen_US
dc.subjectConsensusen_US
dc.subjectCachexiaen_US
dc.subjectImpacten_US
dc.subjectMulticenteren_US
dc.subjectDefinitionen_US
dc.subjectValidationen_US
dc.subjectGuidelinesen_US
dc.titleComparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu